Insitro

Machine learning for drug discovery efficiency

San Francisco, California, United States

About Insitro

Insitro focuses on drug discovery and development in the pharmaceutical research sector. The company utilizes machine learning and biological tools to create predictive models that help identify successful paths for developing new medicines. By doing so, Insitro aims to minimize the costly failures that often occur in pharmaceutical R&D. Their team, which includes scientists and engineers, collaborates to generate and analyze data to enhance the drug discovery process. Unlike traditional methods that rely heavily on intuition, Insitro's approach is data-driven and seeks to provide more accurate predictions. The company primarily serves pharmaceutical companies, healthcare providers, and research institutions looking for efficient drug development solutions. Insitro's goal is to improve the overall effectiveness and efficiency of the drug discovery process.

San Francisco, CaliforniaHeadquarters
2018Year Founded
$625.5MTotal Funding
SERIES_CCompany Stage
AI & Machine Learning, BiotechnologyIndustries
201-500Employees

Benefits

Excellent medical, dental, and vision coverage
Excellent mental health and well-being support
Open vacation policy
Access to free onsite baristas & cafe with daily lunch and breakfast
Access to free onsite fitness center
Commuter benefits
Paid parental leave
Competitive pay and 401(k) matching
Flexible work schedule (on site and remote)

Risks

Competition from well-funded companies like Xaira Therapeutics challenges Insitro's market position.
Ethical concerns in AI drug development may affect Insitro's public perception.
Data privacy issues could lead to regulatory challenges for Insitro.

Differentiation

Insitro integrates machine learning with high-throughput biology for drug discovery.
The company builds predictive models to accelerate target selection and drug development.
Insitro's team combines expertise in science, engineering, and drug discovery.

Upsides

Insitro received $25 million from Bristol Myers Squibb for ALS target discovery.
The company raised over $600 million in venture capital funding.
Insitro appointed AI expert Emily Fox as Senior VP of AI/ML.